Himension Capital Singapore PTE. LTD. Acquires Shares of 4,529 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Himension Capital Singapore PTE. LTD. bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,529 shares of the biopharmaceutical company's stock, valued at approximately $1,066,000.

Several other institutional investors and hedge funds have also modified their holdings of ALNY. Quantbot Technologies LP raised its holdings in Alnylam Pharmaceuticals by 1,754.5% in the 3rd quarter. Quantbot Technologies LP now owns 204 shares of the biopharmaceutical company's stock valued at $56,000 after acquiring an additional 193 shares in the last quarter. Captrust Financial Advisors lifted its position in Alnylam Pharmaceuticals by 34.4% during the third quarter. Captrust Financial Advisors now owns 4,833 shares of the biopharmaceutical company's stock worth $1,329,000 after purchasing an additional 1,237 shares during the period. Quantinno Capital Management LP grew its stake in Alnylam Pharmaceuticals by 50.3% during the third quarter. Quantinno Capital Management LP now owns 3,366 shares of the biopharmaceutical company's stock worth $926,000 after buying an additional 1,126 shares in the last quarter. Kovitz Investment Group Partners LLC bought a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $669,000. Finally, EP Wealth Advisors LLC bought a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $201,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ALNY has been the topic of several analyst reports. William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Canaccord Genuity Group lifted their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a research note on Friday, March 21st. Chardan Capital restated a "buy" rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Sanford C. Bernstein decreased their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. Finally, HC Wainwright reissued a "buy" rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $315.58.

Remove Ads

Insiders Place Their Bets

In related news, CFO Jeffrey V. Poulton sold 967 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $246,749.39. Following the transaction, the chief financial officer now directly owns 32,786 shares of the company's stock, valued at $8,366,003.62. This represents a 2.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the sale, the executive vice president now directly owns 14,321 shares of the company's stock, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,234 shares of company stock worth $19,958,097. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Trading Up 4.1 %

NASDAQ:ALNY traded up $9.33 on Friday, reaching $235.61. 484,775 shares of the stock traded hands, compared to its average volume of 857,669. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The company's 50 day moving average is $253.86 and its 200-day moving average is $258.62. The firm has a market capitalization of $30.65 billion, a price-to-earnings ratio of -108.58 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.